Tyra Prices $400M Offering at $22.03, Led by RA Capital
TYRA sits 85% above its 52-week low of $11.703 on elevated volume (1.8× avg).
Summary
Tyra Biosciences priced an underwritten offering of 9,079,000 common shares at $22.03 and 9,078,529 pre-funded warrants at $22.029, expecting gross proceeds of approximately $400 million. The offering is led by RA Capital Management with participation from Invus, Commodore Capital, BVF Partners, Janus Henderson Investors, and others. Proceeds will fund the dabogratinib 3x3 development strategy in LG-UTUC, IR NMIBC, and achondroplasia, plus preclinical programs and working capital. The deal is expected to close September 15, 2026. This follows the S-3ASR shelf filing earlier today and the FWP announcing the offering; pricing at $22.03 is a modest discount to the last close of $21.70, indicating strong institutional demand. The offering significantly dilutes existing shareholders but extends the cash runway well beyond the $353.9 million reported in Q2 2026.
Updates
· SEC 424B5 — The 424B5 prospectus supplement sets net proceeds at approximately $373.9 million after underwriting discounts and estimated expenses, with delivery expected September 15, 2026.
At the time of this announcement, TYRA was trading at $21.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $11.70 to $40.65. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: PR Newswire.